Related references
Note: Only part of the references are listed.The Proteasome Inhibition Model of Parkinson's Disease
Eduard Bentea et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinson's Disease
Agnieszka Wasik et al.
NEUROTOXICITY RESEARCH (2016)
The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson's disease
Agnieszka Wasik et al.
PHARMACOLOGICAL REPORTS (2016)
Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein
Eduard Bentea et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2015)
An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease
Ilse S. Pienaar et al.
BRAIN STRUCTURE & FUNCTION (2015)
Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra
Jolanta Konieczny et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Protective and toxic roles of dopamine in Parkinson's disease
Juan Segura-Aguilar et al.
JOURNAL OF NEUROCHEMISTRY (2014)
1-Methyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Amine with Unexpected Mechanism of Action: New Vistas of Therapeutic Application
Lucyna Antkiewicz-Michaluk et al.
NEUROTOXICITY RESEARCH (2014)
Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: Behavior, positron emission tomography, immunohistochemistry
Scott Mackey et al.
EXPERIMENTAL NEUROLOGY (2013)
Short and long access to cocaine self-administration activates tyrosine phosphatase STEP and attenuates GluN expression but differentially regulates GluA expression in the prefrontal cortex
Wei-Lun Sun et al.
PSYCHOPHARMACOLOGY (2013)
Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?
Diogo Martins-Branco et al.
EXPERIMENTAL NEUROLOGY (2012)
Parkinson's Disease: Genetics and Pathogenesis
Joshua M. Shulman et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats
Elzbieta Lorenc-Koci et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease
Anthony C. Vernon et al.
BMC NEUROSCIENCE (2010)
Binding of dopamine and 3-methoxytyramine as L-DOPA metabolites to human α2-adrenergic and dopaminergic receptors
Amal Alachkar et al.
NEUROSCIENCE RESEARCH (2010)
Nigral Degeneration with Inclusion Body Formation and Behavioral Changes in Rats after Proteasomal Inhibition
Chaoshi Niu et al.
STEREOTACTIC AND FUNCTIONAL NEUROSURGERY (2009)
3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity
Lucyna Antkiewicz-Michaluk et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration
Xuping Li et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition
Venugopalan D. Nair et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC12 cells
Tae-Beom Ahn et al.
BRAIN RESEARCH (2006)
The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity
L Antkiewicz-Michaluk et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease
K Abe et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Inhibition of MG132-induced mitochondrial dysfunction and cell death in PC12 cells by 3-morpholinosydnonimine
CS Lee et al.
BRAIN RESEARCH (2005)
Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone
L Antkiewicz-Michaluk et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain
L Antkiewicz-Michaluk et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
KS McNaught et al.
NEUROREPORT (2002)
Proteasomal function is impaired in substantia nigra in Parkinson's disease
KSP McNaught et al.
NEUROSCIENCE LETTERS (2001)
Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases
MY Sherman et al.
NEURON (2001)
The endogenous amine 1-methyl-1,2,3,4-tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP+
J Parrado et al.
JOURNAL OF NEUROCHEMISTRY (2000)
Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease
S Kaakkola
DRUGS (2000)
Share Paper
